A new report from UAB demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, proposes race-specific equations to help clinicians better calculate warfarin dosage.
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago. Their findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. Preclinical studies suggest that JAK2 inhibitors may be an effective treatment option for CMML. Eric Padron, M.D., assistant member of the Malignant Hematology Program at Moffitt Cancer Center will report on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago
Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention – the use of agents to prevent the development or progression of prostate cancer. A team of researchers led by Nagi B. Kumar, Ph.D., R.D., F.A.D.A. at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men who have premalignant lesions. The results will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Trending news releases with the most views in a single day. Topics include: income inequality, climate change, genetics, cancer, precision medicine, medical imaging, schizophrenia, research funding, molecular biology and skin cancer.
For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells. The drug has been approved for use in patients in Europe and is in clinical trials in the U.S.
Trending news releases with the most views in a single day. Topics include: genetics and cancer, diabetes and blindness, nanotech, engineering, personalized medicine, energy, and e-cigarettes.
New research has led to FDA approval of the use of a drug to treat the effects of radiation exposure following a nuclear incident. The drug, Neupogen, is the first ever approved for the treatment of acute radiation injury.
Chemists at The Scripps Research Institute have discovered a broad, strikingly inexpensive method for synthesizing “amines,” a class of organic compounds prominent in drugs and other modern products. The new reaction is particularly useful for synthesizing complex amines valuable in pharmaceuticals, but impractical—or impossible—to make with standard methods.
Trending news releases with the most views in a single day. Topics include: gun regulation, psychology and altruism, big data, threats to coral reefs, extra-terrestrial life, personalized diets, metabolic syndrome and heart health, new drug target to treat arthritis, and archeologists find oldest tools.
A novel two-drug combination has the potential to target and restore a defective protein underlying cystic fibrosis (CF), according to two phase III clinical trials conducted at 187 medical centers around the world, including Johns Hopkins.
Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints.
A class of FDA-approved cancer drugs may be able to prevent problems with brain cell development associated with disorders including Down syndrome and Fragile X syndrome, researchers at the University of Michigan Life Sciences Institute have found.
Trending news releases with the most views in a single day. Topics include: nutrition, fibromyalgia, e-cigarettes, cystic fibrosis, asthma, and gluten
Queen's University Belfast has helped to trial a new treatment that could extend the life of cystic fibrosis patients.
Trending news releases with the most views in a single day. Topics include: tick-borne disease, 3D printing, childhood cancer and obesity, nursing, low-back pain, brain cells, and fluid dynamics.
A lot of hard work, practice and dedication can help you sculpt a well-muscled body, but anabolic steroids will get you there a lot faster. What will it cost you, though?
Trending news releases with the most views in a single day. Topics include: WWII and PTSD, stem cells, cancer, racial segregation, supplements and glaucoma, medical research, cybersecurity, vision research, and physics.
With the threat of multidrug-resistant bacterial pathogens growing, new ideas to treat infections are sorely needed. Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report preliminary success testing an entirely novel approach — tagging bacteria with a molecular “homing beacon” that attracts pre-existing antibodies to attack the pathogens.
Trending news releases with the most views in a single day. Topics include: new biotech treatment for radiation proctitis, 3D printing in children's health, work and brain health, the importance of medical research, multi-institute collaboration on medical education technology, tax cuts and the economy, cancer survival, and Alzheimer's research.
Trending news releases with the most views in a single day. Topics include: lung cancer surgery, childhood obesity, physics, imaging, nutrition, civil unrest in Baltimore, Nepal earthquake.
Trending news releases with the most views in a single day. Topics include: Underage drinking, dieting, electrical engineering, neurology and genetics, Nepal earthquake, breast cancer, and supercomputing.
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance.
Trending news releases with the most views in a single day. Topics include: Bruce Jenner and transgender health, agriculture and pesticide alternatives, new tick-borne disease, internal dissent in Iran over nuclear deal, listeria ice cream recalls, changing mammography recommendations, immunology, materials science, and healthcare education.
Trending news releases with the most views in a single day. Topics include: diet supplements and cancer, pancreatic cancer, bird flu, parenting, respiratory health, physics from the DOE office of science, breast cancer awareness, and childhood cancer survivors.
Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.
A new mathematical model that uses drug-target kinetics to predict how drugs work in vivo may provide a foundation to improve drug discovery, which is frequently hampered by the inability to predict effective doses of drugs. The discovery by Peter Tonge, a Professor of Chemistry and Radiology, and Director of Infectious Disease Research at the Institute for Chemical Biology and Drug Discovery (ICB & DD) at Stony Brook University, along with collaborators at Stony Brook University and AstraZeneca, will be published advanced online on April 20 in Nature Chemical Biology.
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. Patients diagnosed with the disease, which is tied to exposure to asbestos, have a median survival rate of about one year.
Trending news releases with the most views in a single day. Topics include: neurology, environment, crowdfunding, engineering, smoking, pharmaceuticals, medical research, cardiology and diabetes
Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication, according to a study in the April 14 issue of JAMA.
Trending news releases with the most views in a single day. Topics include: organic chemistry, cybercrime, pancreatic cancer research from Mayo Clinic, diabetes, pediatrics, new cancer treatment in development at Beth Israel Deaconess Medical Center, pain medicine research from the Ohio State University, marijuana in the workplace, and stem cells
A medicinal liquid form of marijuana may show promise as a treatment for children with severe epilepsy that is not responding to other treatments, according to a study released today that will be presented at the American Academy of Neurology’s 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Cancerous tumors have the ability to evade targeted therapies by activating alternative pathways. Tumors also contain cancer stem cells, believed responsible for metastasis and drug resistance. Now scientists in the Cancer Research Institute at Beth Israel Deaconess Medical Center have identified a drug target that addresses both of these challenges.
Trending news releases with the most views in a single day. Topics include: fertility, same-sex marriage, mobile apps, IL tornado, Clinton running for President, violence against women, CA water crisis, medical research
Researchers studying the commonly used pain reliever acetaminophen found it has a previously unknown side effect: It blunts positive emotions.
Trending news releases with the most views in a single day. Topics include: Astronomy, Cardiology, Nephrology, Neurology, Neutrinos, oil spills, Toxicology, Cancer, and Nutrition
Resistance to therapy is a major problem in the cancer field. Using human cell lines of the HER2-positive breast cancer subtype, researchers detailed the surprising ways in which resistance to the drug lapatinib manifests and how to defeat resistance before it happens.
Trending news releases with the most views in a single day. Topics include: Cancer treatment, meditation, careers in engineering, astronomy, marine conservation, effective dieting, internet marketing, Ebola treatments, and exercise as preventive health for seniors.
Trending news releases with the most views in a single day. Topics include: education, children's health, autism, obesity, smoking, weight loss, LHC re-start, malaria, food safety, kidney disease, and avian flu.
New research forthcoming in Management Science determines that the “shelf life” of malaria-fighting drugs plays a significant role in how donors should subsidize the medicine in order to ensure better affordability for patients.
A commonly prescribed antidepressant caused up to a six-fold increase in atherosclerosis plaque in the coronary arteries of non-human primates, according to a study by researchers at Wake Forest Baptist Medical Center. Coronary artery atherosclerosis is the primary cause of heart attacks.
In the largest study to date documenting the significant risks to children’s health associated with prescription antipsychotics, results suggest that initiating antipsychotics may elevate a child’s risk not only for significant weight gain, but also for Type II diabetes by nearly 50 percent.
Trending news releases with the most views in a single day. Topics include: nanotech treating cancer, immunology, autism, patient monitoring, research ethics, lingering effects of dispersant in Gulf of Mexico, wildlife conservation.
Nathan Mitchell, a graduate student at the University of Texas Health Science Center in San Antonio wanted to know why the therapeutic benefit afforded by SSRIs was so limited in children and teenagers. If researchers can uncover the biological mechanisms preventing available treatments from producing antidepressant effects, scientists can then target those mechanisms to develop new antidepressants that will treat childhood and adolescent depression more effectively.
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.
These data indicate that TG2 is a possible chemotherapeutic target for Glioblastoma Multiforme (GBM) treatment.
Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania.
Antibiotic resistance is poised to spread globally among bacteria frequently implicated in respiratory and urinary infections in hospital settings, according to new research at Washington University School of Medicine in St. Louis.
Magnetic nanoparticles can open the blood-brain barrier and deliver molecules directly to the brain, say researchers from the University of Montreal, Polytechnique Montréal, and CHU Sainte-Justine. This barrier runs inside almost all vessels in the brain and protects it from elements circulating in the blood that may be toxic to the brain. The research is important as currently 98% of therapeutic molecules are also unable to cross the blood-brain barrier.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right